Cell Therapeutics (CTIC +9.9%) shares spike after the company reports its Pixuvri cancer drug is...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC +9.9%) shares spike after the company reports its Pixuvri cancer drug is approved in the EU as monotherapy to treat adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixuvri is the first approved treatment in the EU in this patient setting.